logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Rinat Neuroscience Corporation


USPTO Granted Patents = 52



Forward Citations = 746

Loading Chart...
Loading Chart...

56 inventors (with patents filed for the assignee):

goldMedal Jaume Pons (23 out of 54 patents)

silverMedal David L Shelton (17 out of 44 patents)

bronzeMedal Arnon Rosenthal (16 out of 120 patents)

4.  Pavel Strop (14 out of 27 patents)

5.  Arvind Rajpal (13 out of 44 patents)

6.  Wei-Hsien Ho (12 out of 26 patents)

7.  Yasmina Noubia Abdiche (9 out of 25 patents)

8.  Javier Fernando Chaparro Riggers (8 out of 20 patents)

9.  Magdalena Grazyna Dorywalska (7 out of 8 patents)

10.  Wenwu Zhai (5 out of 12 patents)

11.  Shu-Hui Liu (5 out of 16 patents)

12.  Chia-Yang Lin (5 out of 8 patents)

13.  Bruce Charles Gomes (5 out of 6 patents)

14.  Hong Liang (5 out of 9 patents)

15.  Weihsien Ho (4 out of 9 patents)


Core Competencies:
Antibody-Drug Conjugates
Heterodimeric Proteins
Anti-PD-1 Antibodies
Nerve Growth Factor Antagonists
PCSK9 Antibodies
Trop-2 Antibodies
IL-7 Receptor Antagonists
Amyloid-Beta Peptide Antibodies
Engineered Polypeptide Conjugates
Osteoarthritis Treatment
Bone Cancer Treatment
Obesity Treatment

52 patents:

1. 11602525 - Antibody-drug conjugates with high drug loading (2023-03-14),
2. 11390689 - Heterodimeric proteins and methods for producing and purifying them (2022-07-19),
3. 11338035 - Anti-PD-1 antibodies and methods of use thereof (2022-05-24),
4. 11198735 - Anti-GITR antibodies and methods of use thereof (2021-12-14),
5. 11091544 - Antibodies specific for Trop-2 and their uses (2021-08-17),
6. 11008386 - Anti-NGF antibodies and methods using same (2021-05-18),
7. 10967068 - Stability-modulating linkers for use with antibody drug conjugates (2021-04-06),
8. 10842881 - Engineered polypeptide conjugates using transglutaminase (2020-11-24),
9. 10825548 - Systems and methods of sensing and analyzing antibody blocking interactions (2020-11-03),
10. 10660953 - Anti-PD-1 antibodies and methods of use thereof (2020-05-26),
11. 10323086 - Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same (2019-06-18),
12. 10195289 - Engineered polypeptide conjugates using transglutaminase (2019-02-05),
13. 10155037 - Anti-PD-1 antibodies and methods of use thereof (2018-12-18),
14. 10138303 - Heterodimeric proteins and methods for producing and purifying them (2018-11-27),
15. 10100114 - Antibodies specific for TROP-2 and their uses (2018-10-16),
Rinat Neuroscience Corporation is a leading biopharmaceutical company that specializes in the development and commercialization of innovative treatments for neurological disorders. With a strong focus on neurodegenerative diseases, Rinat Neuroscience aims to improve the lives of patients suffering from conditions such as Alzheimer's, Parkinson's, and Huntington's disease. Combining cutting-edge research with advanced technologies, the company is dedicated to advancing the understanding and treatment of neurological disorders globally.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

52 Patents

#24 in South San Francisco, CA

#1,543 in California

#6,539 in US

#13,151 in the World

...
South San Francisco, CA, United States of America

Rinat Neuroscience Corporation

Forward Citations = 746

56 inventors:

goldMedal Jaume Pons (23 out of 54 patents)

silverMedal David L Shelton (17 out of 44 patents)

bronzeMedal Arnon Rosenthal (16 out of 120 patents)

4.  Pavel Strop (14 out of 27 patents)

5.  Arvind Rajpal (13 out of 44 patents)

Please report any incorrect information to support@idiyas.com
Loading…